文献速递消化与肝胆胰病理细胞病理与分子病理

TUBB3阴性预测不可切除胰腺导管腺癌对白蛋白紫杉醇联合吉西他滨的有利反应

The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma.
PubMed 文献 · Hum Pathol · 2018-01-12

本研究回顾性分析75例接受白蛋白紫杉醇联合吉西他滨(nab-P+Gem)治疗的不可切除胰腺导管腺癌(UR-PDAC)患者,采用EUS-FNA标本免疫组化检测TUBB3表达。67例可分析标本中14例(21%)TUBB3阴性,53例(79%)阳性;阴性患者疾病控制率显著更高(100% vs. 64.2%;P=.008),无进展生存期更长(7.1个月 vs. 3.7个月;P=.036),多因素分析显示TUBB3阴性是PFS延长的独立预测标志(HR=2.41;95%CI 1.11-5.24;P=.026)。

要点

  • EUS-FNA标本免疫组化检测TUBB3阴性可预测UR-PDAC患者对nab-P+Gem的有利反应。
  • TUBB3阴性患者疾病控制率100% vs. 阳性64.2%(P=.008)。
  • TUBB3阴性患者中位PFS 7.1个月 vs. 阳性3.7个月(P=.036)。

核心结论

  • EUS-FNA标本中TUBB3表达缺失可能是UR-PDAC患者对nab-P+Gem反应的有利预测标志。

研究设计与样本

  • 回顾性分析75例接受nab-P+Gem治疗的UR-PDAC患者,采用EUS-FNA标本进行TUBB3免疫组化检测。

主要发现

  • 67例可分析标本中,14例(21%)TUBB3免疫染色阴性,53例(79%)阳性。
  • TUBB3阴性患者疾病控制率显著高于阳性患者(100% vs. 64.2%;P=.008)。
  • TUBB3阴性患者无进展生存期显著长于阳性患者(7.1个月 vs. 3.7个月;log-rank P=.036)。
  • 多因素分析显示TUBB3阴性是PFS延长的独立预测标志(HR=2.41;95%CI 1.11-5.24;P=.026)。

临床怎么用

  • 对拟接受nab-P+Gem治疗的UR-PDAC患者,可考虑通过EUS-FNA标本免疫组化检测TUBB3表达以辅助治疗决策。

局限性

  • 本研究为回顾性分析,样本量有限(75例),结论需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The combined administration of nab-paclitaxel and gemcitabine (nab-P + Gem) is a standard chemotherapy for unresectable pancreatic ductal adenocarcinoma (UR-PDAC); thus, a predictive biomarker to identify patients best suited for nab-P + Gem therapy would be useful. Class III β-tubulin (TUBB3) has been reported to be a predictive marker for taxane resistance in various tumors. However, the correlation between TUBB3 expression and the response to nab-P + Gem in patients with UR-PDAC has not been evaluated. We retrospectively reviewed 75 patients with UR-PDAC who received nab-P + Gem. TUBB3 expression was examined immunohistochemically in specimens obtained by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA). From 67 analyzable specimens that were available for TUBB3 staining, 14 (21%) were negative for TUBB3 immunostaining and 53 (79%) were positive. Patients with negative TUBB3 expression showed a significantly higher disease control rate (100% vs. 64.2%; P = .008) and longer progression-free survival (PFS); (7.1 months vs. 3.7 months; log-rank test, P = .036) than those of patients with positive. Furthermore, negative TUBB3 expression was an independent predictive marker of a prolonged PFS on multivariate analysis (hazard ratio, 2.41; 95% confidence interval, 1.11-5.24; P = .026). Our data indicate that an absence of TUBB3 expression in specimens obtained by EUS-FNA may be a favorable predictive marker of the response to nab-P + Gem in patients with UR-PDAC, highlighting its use as a potential new biomarker for treatment optimization.

来源:Hum Pathol,查看原文。版权归原作者所有。

引用

  1. Kato A, Naiki-Ito A, Naitoh I, et al. The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma. Hum Pathol. 2018. PMID: 29339176. doi:10.1016/j.humpath.2018.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。